AstraZeneca Immuno-Oncology Hopes Buoyed By Tremelimumab
Executive Summary
Quick path to lung cancer approval may not happen for durvalumab, but AstraZeneca could make its immuno-oncology debut with first CTLA-4/PD-L1 combination. Outlook in nephrology is also looking good, firm says at pipeline review.
You may also be interested in...
AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.